Literature DB >> 2383061

Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus.

Y Ishii1, K Nagasawa, T Mayumi, Y Niho.   

Abstract

The clinical importance of IgG anticardiolipin antibodies was investigated in systemic lupus erythematosus (SLE). IgG anticardiolipin antibodies were found in 69 of 155 (44.5%) patients with SLE. Serial measurements of IgG anticardiolipin antibodies allowed the patients to be classified into two groups: group A, persistently positive for IgG anticardiolipin antibodies; group B, positive only in active phases. The IgG anticardiolipin antibody titre in group A was significantly higher than in group B. The incidence of thromboses, spontaneous abortions, and lupus anticoagulant in group A was significantly higher than in group B (p less than 0.05). By contrast, the incidence of renal diseases and anti-dsDNA antibodies in group B was significantly higher than in group A (p less than 0.05). This study showed that group A formed a separate subgroup of patients with SLE who had a high risk of thromboses and spontaneous abortions despite having milder disease activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2383061      PMCID: PMC1004106          DOI: 10.1136/ard.49.6.387

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity.

Authors:  C B Colaço; D K Male
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

Review 2.  Anti-phospholipid antibodies.

Authors:  E N Harris; A E Gharavi; G R Hughes
Journal:  Clin Rheum Dis       Date:  1985-12

3.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

4.  Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  K C Kalunian; J B Peter; H R Middlekauff; J Sayre; D G Ando; M Mangotich; B H Hahn
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

5.  Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.

Authors:  S Loizou; J D McCrea; A C Rudge; R Reynolds; C C Boyle; E N Harris
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

6.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

7.  Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants.

Authors:  H I Glueck; K S Kant; M A Weiss; V E Pollak; M A Miller; M Coots
Journal:  Arch Intern Med       Date:  1985-08

8.  Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus.

Authors:  M D Lockshin; M L Druzin; S Goei; T Qamar; M S Magid; L Jovanovic; M Ferenc
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

9.  The lupus anticoagulant. A disease marker in antinuclear antibody negative lupus that is cross-reactive with autoantibodies to double-stranded DNA.

Authors:  C B Colaco; K B Elkon
Journal:  Arthritis Rheum       Date:  1985-01

10.  Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.

Authors:  T Koike; M Sueishi; H Funaki; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

View more
  14 in total

Review 1.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

2.  Ocular manifestation of systemic lupus erythematosus.

Authors:  Rawhya R El-Shereef; Ahmad Shawkat Mohamed; Lamiaa Hamdy
Journal:  Rheumatol Int       Date:  2011-12-28       Impact factor: 2.631

3.  Retinal disease in patients with systemic lupus erythematosus.

Authors:  O Ushiyama; K Ushiyama; S Koarada; Y Tada; N Suzuki; A Ohta; S Oono; K Nagasawa
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

Review 4.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant.

Authors:  T Mayumi; K Nagasawa; T Inoguchi; Y Yamauchi; Y Ishii; Y Tada; F Umeda; Y Niho
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

6.  Antiphospholipid syndrome: five year follow up.

Authors:  R A Asherson; E Baguley; C Pal; G R Hughes
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

7.  Association of antiphospholipid antibodies with systemic lupus erythematosus in a child presenting with chorea: a case report.

Authors:  N Besbas; I Damarguc; S Ozen; S Aysun; U Saatci
Journal:  Eur J Pediatr       Date:  1994-12       Impact factor: 3.183

8.  Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?

Authors:  A Ghirardello; A Doria; A Ruffatti; A M Rigoli; P Vesco; A Calligaro; P F Gambari
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

9.  The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-beta2-glycoprotein I antibodies.

Authors:  C Neville; J Rauch; J Kassis; S Solymoss; L Joseph; P Belisle; R Subang; E R Chang; P R Fortin
Journal:  Rheumatology (Oxford)       Date:  2006-03-01       Impact factor: 7.580

Review 10.  Diagnosis and pathogenesis of CNS lupus.

Authors:  A P van Dam
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.